CoronaVac疫苗在巴西Gamma变异株流行期对老年人的有效性:检测阴性病例对照研究
该检测阴性病例对照研究纳入巴西圣保罗州43 774名≥70岁居民,评估两剂CoronaVac对症状性新冠及住院、死亡的保护效果。结果显示,第二剂后≥14天对症状性感染有效性46.8%,对住院55.5%,对死亡61.2%,且随年龄增长而下降。
要点
- 第二剂后≥14天对症状性新冠有效性46.8%,对住院55.5%,对死亡61.2%。
- 70-74岁组保护最高:症状性59.0%、住院77.6%、死亡83.9%,随年龄增长下降。
- 完成两剂前保护较低,0-13天症状性有效性仅24.7%。
核心结论
- 在Gamma变异株广泛传播背景下,CoronaVac两剂接种与≥70岁成人症状性新冠、住院和死亡减少相关。
- 疫苗保护在完成两剂方案前较低,且在该老年人群中观察到有效性随年龄增长而下降。
研究设计与样本
- 检测阴性病例对照研究,社区新冠检测人群,巴西圣保罗州。
- 43 774名≥70岁居民,2021年1月17日至4月29日接受RT-PCR检测。
- 26 433例症状性新冠病例与17 622名有症状检测阴性对照,按年龄、性别、自报种族、居住城市、既往新冠状态和检测日期(±3天)匹配成13 283个匹配集,每例匹配至多5名对照。
主要发现
- 第二剂后0-13天对症状性新冠调整有效性24.7%(95%CI 14.7%至33.4%)。
- 第二剂后≥14天对症状性新冠调整有效性46.8%(95%CI 38.7%至53.8%)。
- 第二剂后≥14天对住院调整有效性55.5%(95%CI 46.5%至62.9%),对死亡61.2%(95%CI 48.9%至70.5%)。
- 70-74岁组第二剂后≥14天对症状性新冠有效性59.0%(95%CI 43.7%至70.2%),对住院77.6%(95%CI 62.5%至86.7%),对死亡83.9%(95%CI 59.2%至93.7%),并随年龄增长下降。
临床怎么用
- 对≥70岁老年人应强调完成两剂CoronaVac接种,因完成前保护较低。
- 在高龄老人中应向患者说明疫苗对重症和死亡仍有保护,但有效性随年龄增长而下降。
- 评估老年人接种史时需结合年龄分层理解保护水平,避免将年轻老年人的有效性外推至高龄人群。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To estimate the effectiveness of the inactivated whole virus vaccine, CoronaVac (Sinovac Biotech), against symptomatic covid-19 in the elderly population of São Paulo state, Brazil during widespread circulation of the gamma variant. DESIGN: Test negative case-control study. SETTING: Community testing for covid-19 in São Paulo state, Brazil. PARTICIPANTS: 43 774 adults aged ≥70 years who were residents of São Paulo state and underwent reverse transcription polymerase chain reaction (RT-PCR) testing for SARS-CoV-2 from 17 January to 29 April 2021. 26 433 cases with symptomatic covid-19 and 17 622 test negative controls with covid-19 symptoms were formed into 13 283 matched sets, one case with to up to five controls, according to age, sex, self-reported race, municipality of residence, previous covid-19 status, and date of RT-PCR test (±3 days). INTERVENTION: Vaccination with a two dose regimen of CoronaVac. MAIN OUTCOME MEASURES: RT-PCR confirmed symptomatic covid-19 and associated hospital admissions and deaths. RESULTS: Adjusted vaccine effectiveness against symptomatic covid-19 was 24.7% (95% confidence interval 14.7% to 33.4%) at 0-13 days and 46.8% (38.7% to 53.8%) at ≥14 days after the second dose. Adjusted vaccine effectiveness against hospital admissions was 55.5% (46.5% to 62.9%) and against deaths was 61.2% (48.9% to 70.5%) at ≥14 days after the second dose. Vaccine effectiveness ≥14 days after the second dose was highest for the youngest age group (70-74 years)-59.0% (43.7% to 70.2%) against symptomatic disease, 77.6% (62.5% to 86.7%) against hospital admissions, and 83.9% (59.2% to 93.7%) against deaths-and declined with increasing age. CONCLUSIONS: Vaccination with CoronaVac was associated with a reduction in symptomatic covid-19, hospital admissions, and deaths in adults aged ≥70 years in a setting with extensive transmission of the gamma variant. Vaccine protection was, however, low until completion of the two dose regimen, and vaccine effectiveness was observe to decline with increasing age among this elderly population.
引用
- Ranzani OT, Hitchings MDT, Dorion M, et al. Effectiveness of the CoronaVac vaccine in older adults during a gamma variant associated epidemic of covid-19 in Brazil: test negative case-control study. BMJ. 2021. PMID: 34417194. doi:10.1136/bmj.n2015
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。